cas 609-09-6|| where to buy Diethyl 2-oxomalonate

Nom du produit:Diethyl 2-oxomalonate

IUPAC Name:1,3-diethyl 2-oxopropanedioate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM253990-1000g	in stock	ƥŪȐ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 609-09-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:609-09-6; Formule moléculaire:C7H10O5; Point de fusion:-; Code SMILES:O=C(OCC)C(C(OCC)=O)=O; Densité:

: Numéro de catalogue:CM253990; Poids moléculaire:174.15; Point d'ébullition:209°C at 760 mmHg; N° Mdl:MFCD00009121; Stockage:Keep in inert atmosphere, store at room temperature.

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Sunobinop; Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function.
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.